DMF section 3.2.S.7 - Stability

  Рет қаралды 937

Fernanda Waechter

Fernanda Waechter

Күн бұрын

Пікірлер: 8
@nileshbawane842
@nileshbawane842 8 ай бұрын
Nice explained...
@poonamkamble2976
@poonamkamble2976 6 ай бұрын
Ma'am can you please make a detailed video on new requirements for the CEP content (CEP 2.0). Thank you 😊
@muhammadzende1818
@muhammadzende1818 8 ай бұрын
simple & effective. thanks👍
@Firoz-lm4sz
@Firoz-lm4sz 8 ай бұрын
Good 👍 But you speak very fast In next video please I request you to speak slow for better understanding.
@FernandaWaechter
@FernandaWaechter 8 ай бұрын
Hi dear, sorry that I have spoken a bit faster to avoid the video from getting even longer. If you want, you can choose a slower speed for the video on youtube itself, and most of what I narrate is also written in the video description. Let me know if there is anything you do not understand
@vasanthdola6768
@vasanthdola6768 8 ай бұрын
​@@FernandaWaechter can you explain about NCE minus one and para iv filing
@pullareddykarnati251
@pullareddykarnati251 15 күн бұрын
@@FernandaWaechterk would like to hear from you regarding polymorphism of the drug substances. Could you make a video on this please?
@FernandaWaechter
@FernandaWaechter 14 күн бұрын
@@pullareddykarnati251 thanks for your suggestion, noted!
What is a DMF (drug master file)?
5:40
Fernanda Waechter
Рет қаралды 7 М.
DMF section 3.2.S.1 - General information
4:02
Fernanda Waechter
Рет қаралды 1,1 М.
Quando eu quero Sushi (sem desperdiçar) 🍣
00:26
Los Wagners
Рет қаралды 15 МЛН
Putin urgently interrupted a meeting / Change of power in Ukraine
14:46
DMF seção 3.2.S.7 - Estabilidade
6:38
Fernanda Waechter
Рет қаралды 530
How is the management of DMFs done by API and drug product manufacturers
6:16
3 common interview questions on Forced Degradation
21:14
Pharma Growth Hub
Рет қаралды 22 М.
DMF section 3.2.S.3 - Characterization
6:20
Fernanda Waechter
Рет қаралды 1,1 М.
Which Nerve Agent is the Most Evil? (Nerve Agent Lore)
20:00
That Chemist
Рет қаралды 2 МЛН